IP2IPO invests in Scottish IP (intellectual property) commercialisation fund:
This article was originally published in Clinica
IP2IPO, the London, UK-based intellectual property (IP) company that specialises in commercialising university technology, is extending its interest to Scotland. The AIM-listed firm has subscribed to a 5% stake in Edinburgh-based Sigma Technology Group, with which it will enter a collaboration to support the latter in its efforts to develop IP commercialisation efforts with Scottish universities. It has also take an option to subscribe to an additional 15% stake before June 30 2006.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.